Cabinet approves MSP hike for kharif crops, road project in Andhra; interest subvention scheme for farmers extended
The Union Cabinet also announced railway projects that will benefit Maharashtra and Madhya Pradesh, besides a four-lane highway in the coastal state of Andhra Pradesh.
Coming to the MSP for kharif crops, the government, every year, revises the MSP of key kharif crops ahead of the sowing by farmers, to ensure remunerative prices to the growers for their produce.
This year, the highest absolute increase in MSP over the previous year has been recommended for nigerseed (Rs 820 per quintal) followed by Ragi (Rs 596 per quintal), Cotton (Rs 589 per quintal) and Sesamum (Rs 579 per quintal).
For paddy, it has been raised by Rs 69.
For pulses tur/arhar and moong, it has been raised by Rs 450 and Rs 86, respectively. MSP has been raised for urad by Rs 400.
Coming to oilseeds, MSP for groundnut, sunflower seed, and soybean has been raised by Rs 480, Rs 441, and Rs 436, respectively.
For cotton, MSP has been upped by Rs 589.
The increase in MSP for Kharif Crops for marketing season 2025-26 is in line with the Union Budget 2018-19 announcement of fixing the MSP at a level of at least 1.5 times of the all-India weighted average cost of production.
The expected margin to farmers over their cost of production are estimated to be highest in case of bajra (63 per cent) followed by maize (59 per cent), tur (59 per cent) and urad (53 per cent). For rest of the crops, margin to farmers over their cost of production is estimated to be at 50 per cent.
'In the recent years, the government has been promoting the cultivation of crops, other than cereals such as pulses and oilseeds, and Nutri-cereals/Shree Anna, by offering a higher MSP for these crops,' the government said.
India has three cropping seasons: Summer, Kharif, and Rabi. Kharif crops, sown during June-July and dependent on monsoon rains, are harvested in October-November. Rabi crops, sown in October-November, are harvested from January, depending on their maturity. Summer crops are produced between the Rabi and Kharif seasons.
Moving on to the interest subvention scheme, the Union Cabinet approved the continuation of the scheme for farmers for the financial year 2025-26, and approved required fund arrangements.
It is a Central Sector Scheme aimed at ensuring the availability of short-term credit to farmers at an affordable interest rate through Kisan Credit card (KCC).
Under the Scheme: Farmers received short-term loans of up to Rs 3 lakh through Kisan Credit Cards (KCC) at a subsidized interest rate of 7 per cent, with 1.5 per cent interest subvention provided to eligible lending institutions.
Additionally, farmers repaying loans promptly are eligible for an incentive of up to 3 per cent as Prompt Repayment Incentive (PRI) effectively reducing their interest rate on KCC loans to 4 per cent.
For loans taken exclusively for animal husbandry or fisheries, the interest benefit is applicable up to Rs 2 lakh.
No changes have been proposed in the structure or other components of the scheme by the Cabinet.
'There are more than 7.75 crores of KCC accounts in the country. The continuation of this support is critical to sustaining the flow of institutional credit to agriculture, which is vital for enhancing productivity and ensuring financial inclusion for small and marginal farmers,' the government said in a statement today.
In today's cabinet meeting, two multitracking projects across Indian Railways to ensure seamless and faster transportation of both passengers and goods were approved.
These projects include Ratlam- Nagda 3rd and 4th line; and Wardha- Balharshah 4th line.
The total estimated cost of the projects is Rs 3,399 crore (approx.) and will be completed upto 2029-30.
The two projects covering four Districts across the states of Maharashtra, and Madhya Pradesh, will increase the existing network of Indian Railways by about 176 Kms. The proposed multi-tracking project will enhance connectivity to approx. 784 villages, which are having a population of about 19.74 lakh.
These are essential routes for transportation of commodities such as coal, cement, clinker, gypsum, fly ash, containers, agricultural commodities, and Petroleum products, etc.
In another and last decision, the Cabinet has approved the construction of 4-lane Badvel-Nellore Corridor with a length of 108.134 km for Rs 3,653.10 crore in Andhra Pradesh on NH(67).
The proposed highway will be built on a Design-Build-Finance-Operate-Transfer (DBFOT) mode.
The approved Badvel-Nellore corridor will provide connectivity to important nodes in the three Industrial Corridors of Andhra Pradesh, i.e., Kopparthy Node on the Vishakhapatnam-Chennai Industrial Corridor (VCIC), Orvakal Node on Hyderabad-Bengaluru Industrial Corridor (HBIC) and Krishnapatnam Node on Chennai-Bengaluru Industrial Corridor (CBIC).
Badvel Nellore Corridor starts from Gopavaram Village on the existing National Highway NH-67 in the YSR Kadapa District and terminates at the Krishnapatnam Port Junction on NH-16 (Chennai-Kolkata) in SPSR Nellore District of Andhra Pradesh and will also provide strategic connectivity to the Krishnapatnam Port which has been identified as a priority node under Chennai-Bengaluru Industrial Corridor (CBIC).
The proposed corridor will reduce the travel distance to Krishanpatnam port by 33.9 km from 142 km to 108.13 km as compared to the existing Badvel-Nellore road. This will reduce the travel time by one hour and ensure that substantial gain is achieved in terms of reduced fuel consumption thereby reducing carbon foot print and Vehicle Operating Cost (VOC). The details of project alignment and Index Map is enclosed as Annexure-I. (ANI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
17 minutes ago
- India.com
Masterstroke by Mukesh Ambani as Reliance to invest Rs 4300000000 in Bengaluru-based startup, it deals in..., name is...
Mukesh Ambani (File) In a significant decision which could provide a major boost to India's growing spacetech industry, Mukesh Ambani-led Reliance Industries is mulling to invest $50 million (about Rs 430 crore) in Digantara Research & Technologies, a Bengaluru-based spacetech startup, which is developing technology that can track objects in the Earth's orbit. How much is Mukesh Ambani Reliance Industries investing? According to a report by The Economic Times, Reliance Industries, India's most valued domestic firm led by billionaire Mukesh Ambani, is in advanced discussions to lead a Rs 430 crore funding round in Digantara, along with existing investors like Peak XV Partners. 'Reliance has evaluated multiple startups in the spacetech segment. It is looking at companies building novel solutions in the sector. Its talks with Digantara are at an advanced stage,' the report quoted a source familiar with the matter as saying. What does Digintara do? Co-founded by Anirudh Sharma (CEO), Rahul Rawat (COO), and Tanveer Ahmed (CTO), Digintara is a spacetech startup based in Bengaluru, working on the development of technologies which can track bjects in Earth's orbit. Earlier, in March, Digintara launched a satellite capable of tracking debris as small as 5 cm, and is currently providing services to defence agencies in both India and the United States, as per the report. According to the report, Digintara plans to deploy a constellation of about a dozen surveillance satellites by the end of 2026. The company has launched three satellites so far, one of which is part of the proposed satellite constellation. A major chunk of the upcoming funding round will be dedicated in developing and launching these satellites. 'Given the volatility in global geopolitics, every country is focused on having its own indigenous sovereign solutions that can be controlled in times of crisis. That's where the opportunity lies for startups like Digantara,' the report quoted a source as saying. The company established a manufacturing and operations facility in the US in February 2024, and expects to earn a revenue of $25–30 million (Rs 220–260 crore) from its US operation in the next 2-3 years.
NDTV
31 minutes ago
- NDTV
Hot Dogs, Selfies, Sneakers: Humanoid Robot Grabs New York City's Attention
New Delhi: A humanoid robot marched through Midtown Manhattan last week, causing a stir and drawing shocked stares in the heart of New York City. The robot, branded KOID and priced at around $100,000 (Rs 87.2 lakh), was deployed by global asset management firm KraneShares in a marketing stunt to promote its new Global Humanoid and Embodied Intelligence Index ETF, which launched in June. The robot had previously rung the Nasdaq opening bell. During the stunt, KOID was seen walking along Fifth Avenue, grabbing a hot dog, posing for selfies, and even walking into a Hoka store, where startled staff helped it try on sneakers. The event was filmed and posted to Instagram. View this post on Instagram A post shared by New Yorkers (@newyorkers) A blind man praised the technology as "wonderful," suggesting it could one day help people who can't use guide dogs due to allergies or other issues. Another passerby said, "I mean, I would love for it to clean my house." Not all reactions were positive. "To mess with humanity . . . y'all gotta stop. Satan, I rebuke you to hell," one man yelled. Asked about a potential robot-led future, a woman said, "It's going to happen." The robot was built by Chinese robotics company Unitree and supplied by Long Island-based RoboStore. It operates using Stanford's OpenMind software and, while remote-controlled during the Midtown walk, is fully programmable and already in use at research labs and universities. Since the ETF's launch, KraneShares reports $28 million in assets under management. According to KraneShares' marketing head Joseph Dube, "At some point these robots will be so common that it's not going to have the wow factor that it currently has. We're definitely taking advantage of a moment in time." According to the Morgan Stanley Global Humanoid Model, the humanoid robotics market could grow to 1 billion units and generate $5 trillion in annual revenue by 2050.
India Today
34 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch
